High-content chemical and rnai screens for suppressors of neurotoxicity in a huntington's disease model

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Schulte, Joost ^a   Sepp, Katharine J ^a   Wu, Chaohong ^b   Hong, Pengyu ^b   Littleton, J Troy ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b BRANDEIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CARBENOXOLONE; ETACRYNIC ACID; ETOPOSIDE; GLYCYRRHETINIC ACID; HUNTINGTIN; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; MUTANT PROTEIN; OUABAIN; PHOSPHOTRANSFERASE; POLYGLUTAMINE; PROSCILLARIDIN; PROTEIN INHIBITOR; HD PROTEIN, HUMAN; NERVE PROTEIN; NEUROTOXIN; NUCLEAR PROTEIN;

ALGORITHM; ARTICLE; CHEMICAL COMPOSITION; CONTROLLED STUDY; DISEASE MODEL; DROSOPHILA; DRUG SCREENING; GENE; GENE IDENTIFICATION; GENE SILENCING; HUNTINGTON CHOREA; LKB1 GENE; MAMMAL; MORPHOLOGY; NERVE CELL; NERVE FIBER GROWTH; NEUROTOXICITY; NONHUMAN; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; RNA INTERFERENCE; RNA TRANSLATION; ANIMAL; CELL CULTURE; CHEMISTRY; DROSOPHILA MELANOGASTER; DRUG EFFECT; GENETICS; HIGH THROUGHPUT SCREENING; HUMAN; METABOLISM; METHODOLOGY; NEURITE; PATHOLOGY; PROTEIN QUATERNARY STRUCTURE; REPRODUCIBILITY; SUPPRESSOR GENE;

MAMMALIA;

ALGORITHMS; ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DROSOPHILA MELANOGASTER; GENES, SUPPRESSOR; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; HUNTINGTON DISEASE; MUTANT PROTEINS; NERVE TISSUE PROTEINS; NEURITES; NEURONS; NEUROTOXINS; NUCLEAR PROTEINS; PROTEIN STRUCTURE, QUATERNARY; REPRODUCIBILITY OF RESULTS; RNA INTERFERENCE;

EID: 80052333682     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023841     Document Type: Article

References (78)

1. Kim MW, Chelliah Y, Kim SW, Otwinowski Z, Bezprozvanny I, (2009) Secondary structure of Huntingtin amino-terminal region. Structure 17: 1205-1212.
2. Halliday GM, McRitchie DA, Macdonald V, Double KL, Trent RJ, et al. (1998) Regional specificity of brain atrophy in Huntington's disease. Exp Neurol 154: 663-672.
3. Nopoulos PC, Aylward EH, Ross CA, Johnson HJ, Magnotta VA, et al. (2010) Cerebral cortex structure in prodromal Huntington disease. Neurobiol 40: 544-554 Epub 2010 Aug 2012.
4. Gu X, Li C, Wei W, Lo V, Gong S, et al. (2005) Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 46: 433-444.
5. Paulsen JS, Nopoulos PC, Aylward E, Ross CA, Johnson H, et al. (2010) Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain 82: 201-207 Epub 2010 Apr 2010.
6. Gu X, Andre VM, Cepeda C, Li SH, Li XJ, et al. (2007) Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease. Mol Neurodegener 2: 8.
7. Shin JY, Fang ZH, Yu ZX, Wang CE, Li SH, et al. (2005) Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol 171: 1001-1012.
8. Roze E, Saudou F, Caboche J, (2008) Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments. Curr Opin Neurol 21: 497-503.
9. Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, et al. (2004) Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A 101: 3498-3503 Epub 2004 Mar 3491.
10. Gayan J, Brocklebank D, Andresen JM, Alkorta-Aranburu G, Zameel Cader M, et al. (2008) Genomewide linkage scan reveals novel loci modifying age of onset of Huntington's disease in the Venezuelan HD kindreds. Genet Epidemiol 32: 445-453.
11. Zhang S, Feany MB, Saraswati S, Littleton JT, Perrimon N, (2009) Inactivation of Drosophila Huntingtin affects long-term adult functioning and the pathogenesis of a Huntington's disease model. Dis Model Mech 2: 247-266 Epub 2009 Apr 2006.
12. Li SH, Li XJ, (2004) Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet 20: 146-154.
13. Li Z, Karlovich CA, Fish MP, Scott MP, Myers RM, (1999) A putative Drosophila homolog of the Huntington's disease gene. Hum Mol Genet 8: 1807-1815.
14. Doumanis J, Wada K, Kino Y, Moore AW, Nukina N, (2009) RNAi screening in Drosophila cells identifies new modifiers of mutant huntingtin aggregation. PLoS One 4: e7275.
15. Zhang S, Binari R, Zhou R, Perrimon N, (2010) A genomewide RNA interference screen for modifiers of aggregates formation by mutant Huntingtin in Drosophila. Genetics 184: 1165-1179 Epub 2010 Jan 1125.
16. Robertson AL, Bottomley SP, (2010) Towards the treatment of polyglutamine diseases: the modulatory role of protein context. Curr 17: 3058-3068.
17. Lee W-CM, Yoshihara M, Littleton JT, (2004) Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. Proc Natl Acad Sci USA pp. 3224-3229.
18. Graham R, Deng Y, Slow E, Haigh B, Bissada N, et al. (2006) Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell pp. 1179-1191.
19. Brand AH, Perrimon N, (1993) Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 118: 401-415.
20. Roos RA, (2010) Huntington's disease: a clinical review. Orphanet J Rare Dis 5: 40.
21. DiFiglia M, Sapp E, Chase K, Davies S, Bates G, et al. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science pp. 1990.
22. Sepp KJ, Hong P, Lizarraga SB, Liu JS, Mejia LA, et al. (2008) Identification of neural outgrowth genes using genome-wide RNAi. PLoS Genet 4: e1000111.
23. Wu C, Schulte J, Sepp KJ, Littleton JT, Hong P, (2010) Automatic robust neurite detection and morphological analysis of neuronal cell cultures in high-content screening. Neuroinformatics 8: 83-100.
24. Wang J, Gines S, MacDonald ME, Gusella JF, (2005) Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation. BMC Neurosci 6: 1.
25. Ravikumar B, Vacher C, Berger Z, Davies J, Luo S, et al. (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet pp. 585-595.
26. Hay DG, Sathasivam K, Tobaben S, Stahl B, Marber M, et al. (2004) Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum Mol Genet 13: 1389-1405 Epub 2004 Apr 1328.
27. Zhang X, Smith DL, Meriin AB, Engemann S, Russel DE, et al. (2005) A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc Natl Acad Sci U S A 102: 892-897 Epub 2005 Jan 2010.
28. Chin PC, Liu L, Morrison BE, Siddiq A, Ratan RR, et al. (2004) The c-Raf inhibitor GW5074 provides neuroprotection in vitro and in an animal model of neurodegeneration through a MEK-ERK and Akt-independent mechanism. J Neurochem 90: 595-608.
29. Inoki K, Corradetti MN, Guan KL, (2005) Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37: 19-24.
30. Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, et al. (2004) The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6: 91-99.
31. Hertzberg R, Busby R, Caranfa M, Holden K, Johnson R, et al. (1990) Irreversible trapping of the DNA-topoisomerase I covalent complex. Affinity labeling of the camptothecin binding site. Journal of Biological Chemistry pp. 19287.
32. Shaw R, Lamia K, Vasquez D, Koo S, Bardeesy N, et al. (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science pp. 1642.
33. Hardie D, (2006) Neither LKB1 nor AMPK are the direct targets of metformin. Gastroenterology pp. 973-973.
34. Kao TC, Shyu MH, Yen GC, (2009) Neuroprotective effects of glycyrrhizic acid and 18beta-glycyrrhetinic acid in PC12 cells via modulation of the PI3K/Akt pathway. J Agric Food Chem 57: 754-761.
35. Zoncu R, Efeyan A, Sabatini DM, (2010) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat 12: 21-35 Epub 2010 Dec 2015.
36. Morrisett JD, Abdel-Fattah G, Hoogeveen R, Mitchell E, Ballantyne CM, et al. (2002) Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 43: 1170-1180.
37. Letavernier E, Bruneval P, Mandet C, Duong Van Huyen JP, Peraldi MN, et al. (2007) High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2: 326-333.
38. Kuypers DR, (2005) Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf 28: 153-181.
39. Pham PT, Pham PC, Danovitch GM, Ross DJ, Gritsch HA, et al. (2004) Sirolimus-associated pulmonary toxicity. Transplantation 77: 1215-1220.
40. Maroto JP, Hudes G, Dutcher JP, Logan TF, White CS, et al. (2011) Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol 29: 1750-1756.
41. Martin S, St Johnston D, (2003) A role for Drosophila LKB1 in anterior-posterior axis formation and epithelial polarity. Nature pp. 379-384.
42. Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, et al. (1998) Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 18: 38-43.
43. van Veelen W, Korsse SE, van de Laar L, Peppelenbosch MP, (2011) (2011) The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling.
44. Lee JH, Koh H, Kim M, Park J, Lee SY, et al. (2006) JNK pathway mediates apoptotic cell death induced by tumor suppressor LKB1 in Drosophila. Cell Death Differ 13: 1110-1122.
45. Sarkar S, Perlstein EO, Imarisio S, Pineau S, Cordenier A, et al. (2007) Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat Chem Biol 3: 331-338 Epub 2007 May 2007.
46. Fleming A, Noda T, Yoshimori T, Rubinsztein DC, (2011) Chemical modulators of autophagy as biological probes and potential therapeutics. Nat 7: 9-17.
47. Yamamoto A, Cremona M, Rothman J, (2006) Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway. Journal of Cell Biology pp. 719.
48. David DC, Ollikainen N, Trinidad JC, Cary MP, Burlingame AL, et al. (2010) Widespread protein aggregation as an inherent part of aging in C. elegans. PLoS 8: e1000450.
49. Ju TC, Chen HM, Lin JT, Chang CP, Chang WC, et al. (2011) Nuclear translocation of AMPK-{alpha}1 potentiates striatal neurodegeneration in Huntington's disease. J Cell Biol 194: 209-227.
50. Juszczak GR, Swiergiel AH, (2009) Properties of gap junction blockers and their behavioural, cognitive and electrophysiological effects: animal and human studies. Prog Neuropsychopharmacol Biol Psychiatry 33: 181-198 Epub 2009 Jan 2001.
51. Tamura T, Sone M, Yamashita M, Wanker EE, Okazawa H, (2009) Glial cell lineage expression of mutant ataxin-1 and huntingtin induces developmental and late-onset neuronal pathologies in Drosophila models. PLoS One 4: e4262 Epub 2009 Jan 4223.
52. Bradford J, Shin JY, Roberts M, Wang CE, Sheng G, et al. (2010) Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice. J 285: 10653-10661 Epub 12010 Feb 10659.
53. Kretzschmar D, Tschape J, Bettencourt Da Cruz A, Asan E, Poeck B, et al. (2005) Glial and neuronal expression of polyglutamine proteins induce behavioral changes and aggregate formation in Drosophila. Glia 49: 59-72.
54. Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, et al. (2001) Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 60: 161-172.
55. Lin JH, Weigel H, Cotrina ML, Liu S, Bueno E, et al. (1998) Gap-junction-mediated propagation and amplification of cell injury. Nat Neurosci 1: 494-500.
56. Takeuchi H, Mizoguchi H, Doi Y, Jin S, Noda M, et al. (2011) Blockade of gap junction hemichannel suppresses disease progression in mouse models of amyotrophic lateral sclerosis and Alzheimer's disease. PLoS One 6: e21108.
57. DiFiglia M, Sena-Esteves M, Chase K, Sapp E, Pfister E, et al. (2007) Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A 104: 17204-17209 Epub 12007 Oct 17216.
58. Lang-Rollin IC, Rideout HJ, Noticewala M, Stefanis L, (2003) Mechanisms of caspase-independent neuronal death: energy depletion and free radical generation. J Neurosci 23: 11015-11025.
59. Kluza J, Marchetti P, Gallego MA, Lancel S, Fournier C, et al. (2004) Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene 23: 7018-7030.
60. Reipert S, Berry J, Hughes MF, Hickman JA, Allen TD, (1995) Changes of mitochondrial mass in the hemopoietic stem cell line FDCP-mix after treatment with etoposide: a correlative study by multiparameter flow cytometry and confocal and electron microscopy. Exp Cell Res 221: 281-288.
61. Fu X, Wan S, Lyu YL, Liu LF, Qi H, (2008) Etoposide induces ATM-dependent mitochondrial biogenesis through AMPK activation. PLoS One 3: e2009.
62. Thomas CJ, Rahier NJ, Hecht SM, (2004) Camptothecin: current perspectives. Bioorg Med Chem 12: 1585-1604.
63. Sapp E, Penney J, Young A, Aronin N, Vonsattel JP, et al. (1999) Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. J Neuropathol Exp Neurol 58: 165-173.
64. Gunawardena S, Her LS, Brusch RG, Laymon RA, Niesman IR, et al. (2003) Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 40: 25-40.
65. Trushina E, Dyer RB, Badger JD 2nd, Ure D, Eide L, et al. (2004) Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol 24: 8195-8209.
66. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S, (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431: 805-810.
67. Ambegaokar SS, Roy B, Jackson GR, (2010) Neurodegenerative models in Drosophila: polyglutamine disorders, Parkinson disease, and amyotrophic lateral sclerosis. Neurobiol 40: 29-39 Epub 2010 May 2031.
68. Lim KL, (2010) Non-mammalian animal models of Parkinson's disease for drug discovery. Expert Opin Drug Discov 5: 165-176.
69. O'Kane CJ, (2011) (2011) Drosophila as a Model Organism for the Study of Neuropsychiatric Disorders.
70. Bilen J, Bonini NM, (2005) Drosophila as a model for human neurodegenerative disease. Annu Rev Genet 39: 153-171.
71. Agrawal N, Pallos J, Slepko N, Apostol BL, Bodai L, et al. (2005) Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. Proc Natl Acad Sci U S A 102: 3777-3781.
72. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, et al. (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413: 739-743.
73. Auluck PK, Bonini NM, (2002) Pharmacological prevention of Parkinson disease in Drosophila. Nat Med pp. 1185-1186.
74. Min KT, Benzer S, (1999) Preventing neurodegeneration in the Drosophila mutant bubblegum. Science 284: 1985-1988.
75. Banovic D, Khorramshahi O, Owald D, Wichmann C, Riedt T, et al. (2010) Drosophila neuroligin 1 promotes growth and postsynaptic differentiation at glutamatergic neuromuscular junctions. Neuron 66: 724-738.
76. Williams R, (2006) Development: Neuroligin knockouts: form but no function. Nature Reviews Neuroscience 7: 831.
77. Schulte J, Sepp KJ, Jorquera RA, Wu C, Song Y, et al. (2010) DMob4/Phocein regulates synapse formation, axonal transport, and microtubule organization. J Neurosci 30: 5189-5203.
78. Fisher RA, (1932) Statistical Methods for Research Workers; In: Oliver, Boyd, editors. Edinburgh.